GSK
GSK
763 hedge funds and large institutions have $8.05B invested in GSK in 2016 Q4 according to their latest regulatory filings, with 109 funds opening new positions, 212 increasing their positions, 327 reducing their positions, and 80 closing their positions.
36% more first-time investments, than exits
New positions opened: 109 | Existing positions closed: 80
12% more call options, than puts
Call options by funds: $154M | Put options by funds: $137M
3% more funds holding
Funds holding: 742 → 763 (+21)
0.07% less ownership
Funds ownership: 3.47% → 3.41% (-0.07%)
12% less capital invested
Capital invested by funds: $9.13B → $8.05B (-$1.08B)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
35% less repeat investments, than reductions
Existing positions increased: 212 | Existing positions reduced: 327
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$91.1M |
| 2 |
Two Sigma Advisers
New York
|
+$90.1M |
| 3 |
Renaissance Technologies
New York
|
+$85.2M |
| 4 |
D.E. Shaw & Co
New York
|
+$65.9M |
| 5 |
Millennium Management
New York
|
+$50.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$195M |
| 2 |
JP Morgan Chase
New York
|
-$85.7M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$73.9M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$47.1M |
| 5 |
Neuberger Berman Group
New York
|
-$33.8M |
GSK Hedge Fund Activity: Q4 2016 in Review
763 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q4 2016, worth a combined $8.05B — down 12% from $9.13B a quarter earlier.
Buyers outnumbered sellers: 109 funds opened new GSK positions and 80 closed out — a net gain of 29 holders — while 212 added to existing stakes and 327 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $91.1M. The largest seller was Arrowstreet Capital, exiting entirely with an estimated $195M sold.
- 763 institutional investors held GSK (GSK) as of Q4 2016, up from 742 in Q3 2016.
- Funds reported $8.05B of GSK stock for Q4 2016, down 12% quarter-over-quarter.
- 109 funds opened new GSK positions in Q4 2016 and 80 closed out, a net change of +29 holders.
- The largest GSK buyer in Q4 2016 was T. Rowe Price Associates, an estimated $91.1M added.
- The largest GSK seller in Q4 2016 was Arrowstreet Capital, an estimated $195M sold.
Based on aggregated 13F filings for Q4 2016.